5月8日,辉瑞公司发布消息,其新型抗菌药物思福妥®(注射用头孢他啶阿维巴坦钠)在中国成功获批全年龄段儿童适应症,涵盖从新生儿到青少年的各个年龄段,主要用于治疗由革兰阴性菌引发的复杂性腹腔内感染(cIAI)、医院获得性肺炎和呼吸机相关性肺炎(HAP/VAP),以及针对治疗方案选择有限的儿童感染,为儿童耐药菌感染的治疗带来新的希望。思福妥是一种复方制剂,由第三代头孢菌素头孢他啶和β-内酰胺酶抑制剂阿维...
Source Link5月8日,辉瑞公司发布消息,其新型抗菌药物思福妥®(注射用头孢他啶阿维巴坦钠)在中国成功获批全年龄段儿童适应症,涵盖从新生儿到青少年的各个年龄段,主要用于治疗由革兰阴性菌引发的复杂性腹腔内感染(cIAI)、医院获得性肺炎和呼吸机相关性肺炎(HAP/VAP),以及针对治疗方案选择有限的儿童感染,为儿童耐药菌感染的治疗带来新的希望。思福妥是一种复方制剂,由第三代头孢菌素头孢他啶和β-内酰胺酶抑制剂阿维...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.